Literature DB >> 23250673

Assessing health status in inflammatory bowel disease using a novel single-item numeric rating scale.

Bijal Surti1, Brennan Spiegel, Andrew Ippoliti, Eric A Vasiliauskas, Peter Simpson, David Q Shih, Stephan R Targan, Dermot P B McGovern, Gil Y Melmed.   

Abstract

BACKGROUND: Current instruments used to measure disease activity and health-related quality of life in patients with Crohn's disease (CD) and ulcerative colitis (UC) are often cumbersome, time-consuming, and expensive; although used in clinical trials, they are not convenient for clinical practice. A numeric rating scale (NRS) is a quick, inexpensive, and convenient patient-reported outcome that can capture the patient's overall perception of health. AIMS: The aim of this study was to assess the validity, reliability, and responsiveness of an NRS and evaluate its use in clinical practice in patients with CD and UC.
METHODS: We prospectively evaluated patient-reported NRS scores and measured correlations between NRS and a range of severity measures, including physician-reported NRS, Crohn's disease activity index (CDAI), Harvey-Bradshaw index (HBI), inflammatory bowel disease questionnaire (IBDQ), and C-reactive protein (CRP) in patients with CD. Subsequently, we evaluated the correlation between the NRS and standard measures of health status (HBI or simple colitis clinical activity index [SCCAI]) and laboratory tests (sedimentation rate [ESR], CRP, and fecal calprotectin) in patients with CD and UC.
RESULTS: The patient-reported NRS showed excellent correlation with CDAI (R (2) = 0.59, p < 0.0001), IBDQ (R (2) = 0.66, p < 0.0001), and HBI (R (2) = 0.32, p < 0.0001) in patients with CD. The NRS showed poor, but statistically significant correlation with SCCAI (R (2) = 0.25, p < 0.0001) in patients with UC. The NRS did not correlate with CRP, ESR, or calprotectin. The NRS was reliable and responsive to change.
CONCLUSIONS: The NRS is a valid, reliable, and responsive measure that may be useful to evaluate patients with CD and possibly UC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23250673      PMCID: PMC4161217          DOI: 10.1007/s10620-012-2500-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  51 in total

1.  Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease.

Authors:  Tibor Hlavaty; Philippe Persoons; Severine Vermeire; Marc Ferrante; Marie Pierik; Gert Van Assche; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2006-03       Impact factor: 5.325

Review 2.  Impact of patient-reported outcome measures on routine practice: a structured review.

Authors:  Susan Marshall; Kirstie Haywood; Ray Fitzpatrick
Journal:  J Eval Clin Pract       Date:  2006-10       Impact factor: 2.431

3.  CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease.

Authors:  Alexander D Rodgers; Adrian G Cummins
Journal:  Dig Dis Sci       Date:  2007-04-11       Impact factor: 3.199

4.  The network: a strategy to describe the relationship between quality of life and disease activity. The case of inflammatory bowel disease.

Authors:  H Hjortswang; S Almer; M Ström
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-10       Impact factor: 2.566

5.  Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group.

Authors:  E J Irvine; B Feagan; J Rochon; A Archambault; R N Fedorak; A Groll; D Kinnear; F Saibil; J W McDonald
Journal:  Gastroenterology       Date:  1994-02       Impact factor: 22.682

6.  The performance of three measures of health status in an outpatient diabetes population.

Authors:  M J Bardsley; S Astell; A McCallum; P D Home
Journal:  Diabet Med       Date:  1993 Aug-Sep       Impact factor: 4.359

7.  A simple clinical colitis activity index.

Authors:  R S Walmsley; R C Ayres; R E Pounder; R N Allan
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

8.  Quality of life in treatment of hypertension. A metaanalysis of clinical trials.

Authors:  J A Beto; V K Bansal
Journal:  Am J Hypertens       Date:  1992-03       Impact factor: 2.689

9.  Lack of agreement between patients' and physicians' perspectives of rheumatoid arthritis disease activity changes.

Authors:  B F Leeb; J Sautner; B A Leeb; C Fassl; B Rintelen
Journal:  Scand J Rheumatol       Date:  2006 Nov-Dec       Impact factor: 3.641

10.  Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis.

Authors:  P M Rothwell; Z McDowell; C K Wong; P J Dorman
Journal:  BMJ       Date:  1997-05-31
View more
  4 in total

1.  Does anxiety or waiting time influence patients' tolerance of upper endoscopy?

Authors:  Stefano Pontone; Maya Tonda; Manuela Brighi; Matteo Florio; Daniele Pironi; Paolo Pontone
Journal:  Saudi J Gastroenterol       Date:  2015 Mar-Apr       Impact factor: 2.485

Review 2.  Toward patient-centered care: a systematic review of how to ask questions that matter to patients.

Authors:  Alicia Rosenzveig; Ayse Kuspinar; Stella S Daskalopoulou; Nancy E Mayo
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

3.  Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment.

Authors:  Guillermo Bastida; Claudia Herrera-de Guise; Alicia Algaba; Yolanda Ber Nieto; Jose Manuel Soares; Virginia Robles; Fernando Bermejo; Esteban Sáez-González; Fernando Gomollón; Pilar Nos
Journal:  Nutrients       Date:  2021-05-22       Impact factor: 5.717

4.  Rehabilitation Goals and Effects of Goal Achievement on Outcome Following an Adapted Physical Activity-Based Rehabilitation Intervention.

Authors:  Line Preede; Helene L Soberg; Håkon Dalen; Astrid Nyquist; Reidun Jahnsen; Martin Saebu; Erik Bautz-Holter; Cecilie Røe
Journal:  Patient Prefer Adherence       Date:  2021-07-09       Impact factor: 2.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.